TESARO (TSRO) Misses Q2 EPS by 39c, Cuts FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TESARO Announces Second-Quarter 2018 Operating Results
August 2, 2018 4:05 PM EDTZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status enrollment completedDivestiture completed for VARUBI in U.S. and Canada for $40 million plus potential milestone payments and royaltiesData expected from TSR-042 (anti-PD-1) GARNET NSCLC and MSI-high endometrial expansion cohorts in 2H 2018; regulatory submission planned for 2019
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:... More
